Communication Skills Intervention to Promote Transition Into Survivorship
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.
| Condition |
|---|
|
Hodgkin's Lymphoma Diffuse Large B-cell Lymphoma |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Communication Skills Intervention to Promote Transition Into Survivorship |
- impact on patient outcomes of targeted physician communication skills training [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- impact of a targeted CST intervention on the physicians [ Time Frame: 3 years ] [ Designated as safety issue: No ]use of strategies, tasks and skills about transitioning lymphoma patients from the end of primary treatment to survivorship.
| Estimated Enrollment: | 143 |
| Study Start Date: | November 2011 |
| Estimated Study Completion Date: | November 2014 |
| Estimated Primary Completion Date: | November 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
initial survivorship planning consultation
The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
|
|
initial wellness rehabilitation consultation
The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Patients:
Patients from each site will be recruited from their respective lymphoma services.
Physicians:
Physicians from each site will be recruited from their respective lymphoma services.
Inclusion Criteria:
Physicians:
- who treat patients with DLBCL and HD as per self report
Patients of Physicians:
- have a diagnosis of Hodgkin's or Diffuse Large B-cell Lymphoma as per pathology report or physician assessment in medical record and/or clinical judgment of the treating physician.
For part 1 - have scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment.
For part 2 - have new scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment.
- be at least 18 years old
- speak English well enough, in the judgment of the consenting professional, to be able to understand all aspects of the study, provide informed consent, and be able to complete all study measures.
Exclusion Criteria:
Physicians:
- who do not have adequate patients in their clinical practice to meet the 8 patient enrollment requirement for patients with either DLBCL or HD as per self report
Patients of Physicians:
- show evidence of cognitive impairment severe enough to preclude giving permission to the study staff, or completing the survey instruments of the study.
- as per physician judgment, patient's prognosis and/or co-morbidities make them inappropriate for participation in a survivorship study.
For Part 2 ONLY (longitudinal phase):
- those who consented to part 1, consult recording, of the study.
Contacts and Locations| Contact: Steven Horwitz, MD | 212-639-3045 | |
| Contact: Matthew Matasar, MD | 212-639-8889 |
| United States, Florida | |
| Moffitt Cancer Center | Recruiting |
| Tampa, Florida, United States, 33612 | |
| Contact: Paul Jacobsen, PhD. | |
| Principal Investigator: Paul Jacobsen, PhD | |
| United States, New York | |
| Maimonides Medical Center | Recruiting |
| Brooklyn, New York, United States, 11220 | |
| Contact: Allan B. Astrow, MD | |
| Principal Investigator: Alan B. Astrow, MD | |
| Memorial Sloan-Kettering Cancer Center | Recruiting |
| New York, New York, United States, 10065 | |
| Contact: Steven Horwitz, MD 212-639-3045 | |
| Contact: Matthew Matasar, MD 212-639-8889 | |
| Principal Investigator: Steven Horwitz, MD | |
| United States, Texas | |
| Md Anderson Cancer Center | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Patricia A. Parker, PhD | |
| Principal Investigator: Patricia A. Parker, PhD | |
| Principal Investigator: | Steven Horwitz, MD | Memorial Sloan-Kettering Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT01483664 History of Changes |
| Other Study ID Numbers: | 11-180 |
| Study First Received: | November 29, 2011 |
| Last Updated: | November 30, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Memorial Sloan-Kettering Cancer Center:
|
patient outcomes Survivorship Communication Skills |
Communication strategies Physicians communication 11-180 |
Additional relevant MeSH terms:
|
Hodgkin Disease Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin |
ClinicalTrials.gov processed this record on May 22, 2013